Sagimet Biosciences Inc (SGMT)
4.32
-0.13
(-2.92%)
USD |
NASDAQ |
May 03, 16:00
4.32
0.00 (0.00%)
After-Hours: 20:00
Sagimet Biosciences Free Cash Flow (Quarterly): -7.083M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -7.083M |
| September 30, 2023 | -3.879M |
| June 30, 2023 | -5.72M |
| March 31, 2023 | -7.084M |
| December 31, 2022 | -7.453M |
| Date | Value |
|---|---|
| September 30, 2022 | -6.234M |
| June 30, 2022 | -6.138M |
| March 31, 2022 | -4.665M |
| March 31, 2021 | -4.903M |
| March 31, 2020 | -2.598M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-7.453M
Minimum
Dec 2022
-2.598M
Maximum
Mar 2020
-5.576M
Average
-5.929M
Median
Free Cash Flow (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -80.97M |
| 89bio Inc | -34.29M |
| Viking Therapeutics Inc | -6.134M |
| Akero Therapeutics Inc | -48.63M |
| Arrowhead Pharmaceuticals Inc | -186.50M |